Arix Bioscience PLC (LON:ARIX) said an investee company has “in-licensed” an ATR inhibitor programme from one of the world’s leading cancer centres and a venture capital firm.
Artios Pharma’s exclusive deal with The University of Texas MD Anderson Cancer Center and ShangPharma Innovation strengthens the company’s earlier-stage pipeline focused on the area of DNA damage response.
DDR is a network of cellular pathways that sense, signal and repair DNA lesions.
Surveillance proteins that monitor DNA integrity can activate cell cycle checkpoints and DNA repair pathways in response to DNA damage, to prevent the generation of potentially harmful mutations.
Arix investment director, Jonathan Tobin, who is also an Artios board member, said he was pleased to see the firm’s pipeline “continue to grow and mature”.
“This deal, coupled with Artios’ significant expertise in this field, reinforces its position as the world leader in this exciting new space in oncology,” he added.